Should You Buy Canopy Growth Stock on the Rebound?
Canopy Growth is a large Canadian marijuana company. Over the past year, it has strengthened its financial position and made an acquisition.
CGC - Canopy Growth Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$14.47
DETAILS
HIGH:
$27.85
LOW:
$8.00
MEDIAN:
$11.02
CONSENSUS:
$14.47
UPSIDE:
1387.61%
Stock News
Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?
Tilray is seeing more revenue from beverages than from cannabis. Canopy's debt situation drags down its growth potential.
3 Top Marijuana Stocks to Watch in September 2026
The cannabis industry is entering September, and investors are once again searching for opportunities across the sector. After years of volatility, several marijuana companies are showing signs of stronger financial performance. Revenue is improving for some operators. Meanwhile, others are cutting costs, strengthening margins, and expanding internationally. That combination could put marijuana stocks back on investors' radar. However, this is no longer simply a story about rapid expansion. Investors are becoming more selective about which cannabis companies deserve their attention. Today, profitability matters. Cash flow matters. Additionally, investors want companies with strong brands and opportunities beyond their existing markets. International cannabis growth has become particularly important. Europe continues expanding its medical cannabis industry. As a result, Canadian producers are positioning themselves to capture growing international demand. Meanwhile, the United States remains an important potential catalyst. Changes to federal cannabis regulations could eventually reshape the industry's investment landscape.
Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?
Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.
Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD
Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names.
Top Canadian Cannabis Stocks to Watch in August 2026
Canadian cannabis stocks are once again gaining attention as investors search for opportunities within the global marijuana industry. The sector has experienced significant changes since Canada legalized recreational cannabis in 2018. However, several leading companies have emerged stronger after years of restructuring, cost reductions, and increased competition.
Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the Company has mailed (or mailed a notice of internet availability with respect to) its proxy statement and fiscal 2026 annual report to shareholders (collectively, the “Meeting Materials”) for its Annual General and Special Meeting of shareholders (the “Meeting”) sche.
Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?
Curaleaf's bid signals cannabis consolidation is accelerating. Canopy Growth could emerge as another takeover candidate.
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.
Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced that its Kincardine, Ontario cultivation facility (“Kincardine”) has received renewed European Union Good Manufacturing Practice (“EU GMP”) certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg. With its EU GMP status.
Will Canopy Growth Get Acquired?
Curaleaf recently announced plans for a takeover of Aurora Cannabis, a rival of Canopy Growth. Canopy Growth is an iconic cannabis company in Canada with a strong position in the market.
Canopy Growth Targets European Cannabis Expansion After MTL Deal and Cost Cuts
Canopy Growth NASDAQ: CGC is positioning itself for further expansion in medical cannabis, European markets and Canadian recreational cannabis after restructuring operations, reducing costs and acquiring MTL Cannabis, President and CEO Luc Mongeau said during a Canaccord Genuity presentation.
Canopy Growth: Penny Stock Purgatory -- or Cannabis Rebound in the Making?
Canopy's balance sheet is finally improving. Medical cannabis is driving the strongest growth.
Why Rescheduling Might Not Move Canopy Growth's Stock as Much as You Think
The United States is slowly moving toward the legalization of marijuana. The next big step is the rescheduling of the drug at the federal level, which won't make it legal, just less illegal.
Canopy Growth Q1 Earnings Call Highlights
Canopy Growth NASDAQ: CGC reported first-quarter fiscal 2027 net revenue of C$81.2 million, up 13% from the prior-year period, as the company recorded year-over-year growth across its cannabis and Storz & Bickel businesses.
Canopy Growth reports fiscal first quarter revenue growth, improved margins
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported continued revenue growth across its businesses in the first quarter of fiscal 2027, while the cannabis company narrowed its adjusted EBITDA loss from a year earlier, sending its shares 5% higher on Friday morning. Net revenue for the three months ended June 30, 2026, increased 13% year-over-year to C$81.2 million, exceeding the analyst consensus estimate of C$58.89 million.
Canopy Growth Sees Steady Progress on Profitability Measures
Canopy Growth Corporation (NASDAQ:CGC) on Friday reported a first-quarter fiscal 2027 loss of two cents (three Canadian cents) per share, compared to the consensus loss of four cents (five Canadian cents).
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.
Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses.
Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses
Canopy Growth Corporation (âCanopy Growthâ, âourâ, âweâ or the âCompanyâ) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bette
Price Targets
Canopy Growth price target lowered to C$11 from C$18 at Alliance Global Partners
$11.00
(was $8.21)
Aaron Grey
·
Alliance Global Partners
Canopy Growth initiated with an Underweight at Wells Fargo
$8.00
(was $10.15)
Derek Archila
·
Wells Fargo
Jefferies Keeps a Hold Rating on Canopy Growth (CGC)
$16.70
(was $11.62)
Owen Bennett
·
Jefferies
Canopy Growth price target lowered to C$35 from C$55 at Desjardins
$35.00
(was $25.27)
John Chu
·
Desjardins